Zobrazeno 1 - 10
of 1 290
pro vyhledávání: '"Anti-drug antibodies"'
Autor:
Paul Chamberlain, Bernhard Hemmer, Josef Höfler, Hendrik Wessels, Oliver von Richter, Cyrill Hornuss, Johann Poetzl, Karsten Roth
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundBiosimilar natalizumab (biosim-NTZ) is the first biosimilar monoclonal antibody of reference natalizumab (ref-NTZ) for treatment of relapsing forms of multiple sclerosis (MS). Within the totality of evidence for demonstration of biosimilari
Externí odkaz:
https://doaj.org/article/c4cac83de4564f1384504ffcaaedd5cd
Autor:
Steven James Swanson
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The FDA has released new draft guidance to standardize how immunogenicity of protein therapeutics is described in product labels. A key aspect to this new guidance is that companies should describe anti-drug antibodies that have clinical significance
Externí odkaz:
https://doaj.org/article/df11cad646254a54a7215ec88bc3123d
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
Autor:
Nicole L. Jarvi, Manali Patel, Krithika A. Shetty, Nhan H. Nguyen, Brooke F. Grasperge, Donald E. Mager, Robert M. Straubinger, Sathy V. Balu-Iyer
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionImmunogenicity continues to be a challenge for development and clinical utility of monoclonal antibodies, and there are gaps in our current ability to prevent anti-drug antibody development in a safe and antigen-specific manner.MethodsTo
Externí odkaz:
https://doaj.org/article/7c7da71065644d71b0fbb527a18021ab
Autor:
Wen-Ting K. Tsai, Yinyin Li, Zhaojun Yin, Peter Tran, Qui Phung, Zhenru Zhou, Kun Peng, Dan Qin, Sien Tam, Christoph Spiess, Jochen Brumm, Manda Wong, Zhengmao Ye, Patrick Wu, Sivan Cohen, Paul J. Carter
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
Bispecific antibodies, including bispecific IgG, are emerging as an important new class of antibody therapeutics. As a result, we, as well as others, have developed engineering strategies designed to facilitate the efficient production of bispecific
Externí odkaz:
https://doaj.org/article/9805ef0547804dc680ba4370dfa5869f
Autor:
Aimee E. Mattei, Andres H. Gutierrez, Soorya Seshadri, Jacob Tivin, Matt Ardito, Amy S. Rosenberg, William D. Martin, Anne S. De Groot
Publikováno v:
mAbs, Vol 16, Iss 1 (2024)
In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is ‘fully human’, T cell epitopes that are contain
Externí odkaz:
https://doaj.org/article/d3ac97f35912434aae9b77e2b10534c0
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiaoliang Ding, Ling Xue, Mingjun Wang, Shengxiong Zhu, Kouzhu Zhu, Sheng Jiang, Jian Wu, Liyan Miao
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundAdalimumab induces the production of anti-drug antibodies (ADA) that may lead to reduced drug concentration and loss-of-response, posing significant clinical challenges. However, traditional immunoassays have limitations in terms of sensiti
Externí odkaz:
https://doaj.org/article/430ac58bb13b40348b442c36d8bfe89c
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 208-215 (2024)
Introduction. Adalimumab, a fully humanized monoclonal antibody, is a tumor necrosis factor (TNFα) inactivator that is used against a number of autoimmune diseases such as rheumatoid arthritis and other most common inflammatory arthropathies (ankylo
Externí odkaz:
https://doaj.org/article/61c7f9e522ba49819af0b0a58b6b54e9
Autor:
A. N. Afanaseva, V. B. Saparova, I. E. Makarenko, T. A. Selmenskikh, D. V. Kurkin, A. L. Hohlov, R. V. Drai
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 247-255 (2024)
Introduction. Romiplostim is an analogue of the fusion protein peptide of thrombopoietin (TPO), which increases platelet count by binding and activating the human thrombopoietin receptor (TPO-R). It is used to treat thrombocytopenia associated with c
Externí odkaz:
https://doaj.org/article/b275653dfe8748d792b2e41f4c5157b3
Autor:
Renzo Mignani, Claudio Americo, Filippo Aucella, Yuri Battaglia, Vittoria Cianci, Annamaria Sapuppo, Chiara Lanzillo, Fabio Pennacchiotti, Luciano Tartaglia, Giacomo Marchi, Federico Pieruzzi
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-9 (2024)
Abstract Background Fabry disease is a rare progressive X-linked lysosomal storage disease caused by mutations in the GLA gene that encodes α-galactosidase A. Agalsidase beta is a recombinant enzyme replacement therapy authorized in Europe at a stan
Externí odkaz:
https://doaj.org/article/c127f7d8ac8b440fad79006e7c98871d